MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, June 8, 2008

New drug (frampridine) to tackle MS mobility disorders

New drug to tackle MS mobility disorders
Press TV
Sat, 07 Jun 2008 19:22:25
A newly developed medicine has shown promising results in fighting mobility disorders in patients suffering from multiple sclerosis.

According to the new reports, frampridine improves walking skills in two-fifths of the patients taking the drug and positively influences leg strength in the majority of these individuals.

Findings revealed that the medication made by Acorda co. improves the condition by slowing the loss of potassium from nerve cells caused by the underlying disease.

The study reported that while the drug improved mobility in some patients, it had no effect on the overall speed of the disease in such individuals.

British MS Society researches believe the new drug has a considerable impact on the quality of life in MS patients particularly those who are still capable of walking, but at a slow pace and with difficulty.

Multiple sclerosis is an autoimmune condition in which the immune system attacks the myelin covering the nerve cells, leading to numerous physical and mental symptoms including limb weakness, blurred vision and balance problems.


1 comment:

Lauren said...

From what I understand, because Fampridine can be used in conjunction with other therapies (the ABCRs & Tysabri), the MS patient does not have to switch therapies, but only consider Fampridine as an "add-on" therapy to assist them with their walking, if they are still ambulatory.

Fampridine does not alter the immune system, so it is apparently safe as an "add-on" therapy for the patient, plus it's a pill, yaaay!

I think this is wonderful news for the appropriate MS community.

Jmho, Lauren :)